Abstract：Objective: To explore the clinical effects of ultra-early application of alteplase intravenous thrombolysis on cerebral infarction and its influence on clinical outcomes. Methods: From January 2017 to January 2019, 96 patients with cerebral infarction in our hospital were selected. According to different treatment methods, they were divided into control group and study group, 48 cases in each group. Control group was given combined treatment of Bayaspirin enteric-coated tablets, clopidogrel hydrogen sulphate tablets and Shuxuetong injection while study group was given ultra-early application of alteplase intravenous thrombolysis, and given routine administration of Bayaspirin enteric-coated tablets and clopidogrel hydrogen sulphate tablet after 24hs, and method and dose in study group were the same as control group, and they were treated for 2 weeks. The neurological deficit, daily living ability, inflammatory factors levels, central nervous system-specific protein level, neuro-specific enolase level, coagulation function and adverse reactions after administration were compared between the two groups. Results: There were no adverse reactions in study group, and there was no significant difference compared with 2.08% in control group (P>0.05). The neurological deficit score, Barthel index score, S100β level, NSE level and various inflammatory factors in the two groups were effectively improved after treatment, and the improvements in study group were better than those in control group (P<0.05). After treatment, the plasma fibrinogen FIB of the two groups was significantly decreased (P<0.05). However, there were no significant differences in the coagulation function indexes between the two groups (P<0.05). Conclusion: Ultra-early alteplase intravenous thrombolysis has reliable effects and good safety in the treatment of patients with cerebral infarction, thus it is worthy of promotion.
王赫, 孙元林. 超早期应用阿替普酶静脉溶栓对于脑梗死患者临床转归的影响分析[J]. 河北医学, 2020, 26(2): 286-289.
WANG He, SUN Yuanlin. Effects of Ultra-early Application of Alteplase Intravenous Thrombolysis on Clinical Outcomes of Patients with Cerebral Infarction. HeBei Med, 2020, 26(2): 286-289.
2020, Vol. 26 
冀公网安备13080202000677号